Kyverna Therapeutics Email Format

Biotechnology ResearchCalifornia, United States51-200 Employees

Kyverna Therapeutics is a clinical-stage biotechnology company located in Emeryville, California, focused on developing cell therapies to treat autoimmune diseases. Its lead autologous CD19-targeting CAR T-cell candidate aims to deplete B cells and reduce autoantibody activity, with the goal of changing how B-cell–driven autoimmune diseases are treated. The company is building a neuroimmunology-focused program that includes registrational trials in stiff person syndrome and generalized myasthenia gravis, while pursuing indications in multiple sclerosis and rheumatoid arthritis.

Its broader pipeline envisions next-generation CAR T-cell therapies designed to improve patient access and experience. Kyverna operates in the biotechnology research industry and positions itself as a clinical-stage player pursuing therapies for autoimmune conditions through personalized immune cell approaches. In 2026, the company announced leadership updates, including the appointment of a Chief Commercial Officer.

Get verified Kyverna Therapeutics emails free

Company overview Employee directory